BackTelomir Pharmaceuticals Overview

Telomir Pharmaceuticals Current Cash

Track Telomir Pharmaceuticals's current cash ($5.2M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$5.17M
↑ 585.42% YoYΔ $4.42M vs prior year quarter

Peer trimmed avg / median

Loading

Telomir Pharmaceuticals Current Cash History

Loading

Telomir Pharmaceuticals vs. peers: Current Cash Comparison

Loading

Telomir Pharmaceuticals Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Telomir Pharmaceuticals (TELO) FAQ

Telomir Pharmaceuticals posts a current cash of $5.2M as of June 2026. That compares with $750K in the prior-year period — up 585.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Telomir Pharmaceuticals's current cash was $750K. The latest reading is $5.2M — a 585.4% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Current Cash is one piece of Telomir Pharmaceuticals's financial statement story. At $5.2M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for TELO's current cash usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Telomir Pharmaceuticals's other metric pages and overview cover the third.